A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06248008
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT06192264
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05718518
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05596045
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Aga Clinical Trials, Hialeah, Florida, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05523141
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT05330143
- Locations
- 🇨🇳
The Fifth Medical Center of the General Hospital of the Peoples Liberation Army, Beijing, Beijing, China
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
- Conditions
- Interventions
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT05118776
- Locations
- 🇨🇳
Beijing Tiantan Hospital，Capital Medical University, Beijing, Beijing, China
Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT05107778
- Locations
- 🇨🇳
NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05104125
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04965337
- Locations
- 🇨🇳
Xiangya Boai Rehabilitation Hospital, Changsha, Hunan, China